Enigma Diagnostics appoints Dr Lynn Busteed as CEO

Enigma Diagnostics has announced the appointment of Dr Lynn Busteed as Chief Executive Officer (CEO) and a member of the Board of Directors.

This appointment completes Enigma Diagnostics' executive management team following the recent appointments of Biresh Roy as Chief Financial Officer and Mo Aslam as Programme Director.

Dr Busteed has more than 15 years experience in the life sciences sector, specialising in corporate and business development, strategic planning and operations. She joins Enigma from Focus Diagnostics, Inc., a US-based company providing products and services for the diagnosis of infectious diseases. At Focus Diagnostics, Dr Busteed was Vice President for Corporate Development with responsibility for a broad range of business development, licensing and M&A activities and a particular emphasis on acquisition of platforms and technology to fuel growth of the diagnostics products business.

From 2001 to 2004, Dr Busteed was Senior Director, Business Development and Strategic Planning at US company Celera Genomics Group (NYSE:CRA), a leader in the field of targeted medicine based on its genomics, proteomics and molecular diagnostics businesses.

Prior to this she spent seven years at management consulting firm McKinsey & Company in France and the UK where she gained broad experience in both strategic and operational consulting focusing on healthcare, chemicals and basic materials industries.

John McKinley, Chairman of Enigma Diagnostics, said: "I am extremely pleased that we have been able to attract Lynn to lead Enigma's executive team at this important phase of our development. Her experience is highly relevant to the company's product growth and to our broad US and European market focus. Lynn's appointment significantly strengthens the team that we have been building over the past six months and we warmly welcome her to Enigma."

Lynn Busteed added: "I have been strongly impressed with the high quality of Enigma's technology and the strength of the management team that has been assembled. I very much look forward to working with Enigma to realize its ambitious goals for the development and growth of products to target the global diagnostics markets for infectious diseases."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Rapid molecular assay to detect SARS-CoV-2-specific RNA sequences